We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Oracle, SAP, Cigna and Walgreens Boots Alliance
Read MoreHide Full Article
For Immediate Release
Chicago, IL – July 26, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Johnson & Johnson (JNJ - Free Report) , Oracle Corporation (ORCL - Free Report) , SAP SE (SAP - Free Report) , Cigna Corporation (CI - Free Report) and Walgreens Boots Alliance, Inc. (WBA - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Research Reports for Johnson & Johnson, Oracle and SAP
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson, Oracle, and SAP. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of Johnson & Johnson have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+18.6% vs. +18.3%) on the back of the company's rapid progress with its pipeline and line extensions, with several pivotal data readouts and regulatory milestones expected in the near term. The company's beat-and-raise quarterly report in recent days should help sustain this performance momentum.
Successful label expansion of drugs like Imbruvica, Darzalex and Stelara has been supporting its Pharma unit. The Medical Devices segment is demonstrating a strong recovery from weak sales during the early stages of the pandemic. Generic competition and pricing pressure still remain as major headwinds though. Numerous lawsuits, alleging personal injuries to patients caused by the use of its products, are also a concern.
Oracle shares have gained +46% over the last six months against the Zacks Computer Software industry's gain of +24%, with the company benefiting from the ongoing momentum in its cloud business, driven by strong uptake of Oracle Cloud Infrastructure (OCI) services and Autonomous Database offerings.
Healthy adoption of cloud-based applications such as NetSuite Enterprise Resource Planning (ERP), Fusion ERP and Fusion Human Capital Management (HCM) bodes well in the long term. Increased spending, however, on product enhancements amid stiff competition in the cloud market is likely to limit its margin expansion.
Shares of SAP have gained +7.5% in the year to date period against the Zacks Computer Software industry's gain of +25.5%, however, its Q2 performance reflected continued strength in its cloud business. The Zacks analyst believes that the company's dominance in providing efficient customer engagement, human capital management as well as interconnected commerce network bodes well.
SAP's alliances with IBM, Microsoft and Verizon favor business prospects. Solid demand for e-commerce, digital supply chain and other cloud platform solutions, also supports growth in the long term. Soft uptake of software licenses and support offerings and increasing investments to enhance cloud-based offerings are major concerns though.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Johnson & Johnson, Oracle, SAP, Cigna and Walgreens Boots Alliance
For Immediate Release
Chicago, IL – July 26, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Johnson & Johnson (JNJ - Free Report) , Oracle Corporation (ORCL - Free Report) , SAP SE (SAP - Free Report) , Cigna Corporation (CI - Free Report) and Walgreens Boots Alliance, Inc. (WBA - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Research Reports for Johnson & Johnson, Oracle and SAP
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson, Oracle, and SAP. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Shares of Johnson & Johnson have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+18.6% vs. +18.3%) on the back of the company's rapid progress with its pipeline and line extensions, with several pivotal data readouts and regulatory milestones expected in the near term. The company's beat-and-raise quarterly report in recent days should help sustain this performance momentum.
Successful label expansion of drugs like Imbruvica, Darzalex and Stelara has been supporting its Pharma unit. The Medical Devices segment is demonstrating a strong recovery from weak sales during the early stages of the pandemic. Generic competition and pricing pressure still remain as major headwinds though. Numerous lawsuits, alleging personal injuries to patients caused by the use of its products, are also a concern.
(You can read the full research report on Johnson & Johnson here >>>)
Oracle shares have gained +46% over the last six months against the Zacks Computer Software industry's gain of +24%, with the company benefiting from the ongoing momentum in its cloud business, driven by strong uptake of Oracle Cloud Infrastructure (OCI) services and Autonomous Database offerings.
Healthy adoption of cloud-based applications such as NetSuite Enterprise Resource Planning (ERP), Fusion ERP and Fusion Human Capital Management (HCM) bodes well in the long term. Increased spending, however, on product enhancements amid stiff competition in the cloud market is likely to limit its margin expansion.
(You can read the full research report on Oracle here >>>)
Shares of SAP have gained +7.5% in the year to date period against the Zacks Computer Software industry's gain of +25.5%, however, its Q2 performance reflected continued strength in its cloud business. The Zacks analyst believes that the company's dominance in providing efficient customer engagement, human capital management as well as interconnected commerce network bodes well.
SAP's alliances with IBM, Microsoft and Verizon favor business prospects. Solid demand for e-commerce, digital supply chain and other cloud platform solutions, also supports growth in the long term. Soft uptake of software licenses and support offerings and increasing investments to enhance cloud-based offerings are major concerns though.
(You can read the full research report on SAP here >>>)
Other noteworthy reports we are featuring today include Cigna and Walgreens Boots Alliance.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.